New HIV/AIDS vaccines study findings have been reported by E. Sandström and co-researchers
December 1st, 2008
2008 DEC 1 -- Investigators publish new data in the report 'Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara.' According to recent research from Sweden, "A human immunodeficiency virus (HIV) vaccine that limits disease and transmission is urgently needed. This clinical trial evaluated the safety and immunogenicity of an HIV vaccine that combines a plasmid-DNA priming vaccine and a modified vaccinia virus Ankara (MVA) boosting vaccine."
"Forty healthy volunteers were injected with DNA plasmids containing gp160 of HIV-1 subtypes A, B, and C; rev B; p17/p24 gag A and B, and RTmut B by use of a needle-free injection system. The vaccine was administered intradermally or intramuscularly, with or without recombinant granulocyte macrophage colony-stimulating factor, and boosted with a heterologous MVA containing env, gag, and pol of CRF01A_E. Immune responses were monitored with HIV-specific interferon (IFN)-gamma and interleukin (IL)-2 ELISpot and lymphoproliferative assays (LPAs). Vaccine-related adverse events were mild and tolerable. After receipt of the DNA priming vaccine, 11 (30%) of 37 vaccinees had HIV-specific IFN-gamma responses. After receipt of the MVA boosting vaccine, ELISpot assays showed that 34 (92%) of 37 vaccinees had HIV-specific IFN-gamma responses, 32 (86%) to Gag and 24 (65%) to Env. IFN-gamma production was detected in both the CD8(+) T cell compartment (5 of 9 selected vaccinees) and the CD4(+) T cell compartment (9 of 9). ELISpot results showed that 25 (68%) of 37 vaccinees had a positive IL-2 response and 35 (92%) of 38 had a positive LPA response. Of 38 subjects, a total of 37 (97%) were responders. One milligram of HIV-1 DNA administered intradermally was as effective as 4 mg administered intramuscularly in priming for the MVA boosting vaccine. This HIV-DNA priming-MVA boosting approach is safe and highly immunogenic," wrote E. Sandström and colleagues, .
The researchers concluded: "TRIALS REGISTRATION: International Standard Randomised Controlled Trial number: ISRCTN32604572 ."
Sandström and colleagues published their study in the Journal of Infectious Diseases (Broad immunogenicity of a multigene, multiclade HIV-1 DNA vaccine boosted with heterologous HIV-1 recombinant modified vaccinia virus Ankara. Journal of Infectious Diseases, 2008;198(10):1482-90).
For additional information, contact E. Sandström, Sodersjukhuset, Dept. of Clinical Science and Education, Sweden.
Publisher contact information for the Journal of Infectious Diseases is: University Chicago Press, 1427 E 60th St., Chicago, IL 60637-2954, USA.
Keywords: Sweden, HIV/AIDS Vaccines, AIDS, Acquired Immune Deficiency Syndrome, Acquired Immunodeficiency Syndrome, Adverse Drug Effect, Adverse Drug Event, Adverse Drug Reaction, Biotechnology, Clinical Trial Research, DNA Research, DNA Vaccines, HIV, Human Immunodeficiency Virus, Immunization, Immunology, Interferon, Medical Device, Sexually Transmitted Disease, Therapy, Treatment, Vaccination, Vaccinia Virus, Viral, Virology.
This article was prepared by AIDS Vaccine Week editors from staff and other reports. Copyright 2008, AIDS Vaccine Week via NewsRx.com.
